Add on SGLT2 inhibitors to insulin therapy in diabetes patients lowers blood sugar, BP, and weight without reducing eGFR

The team in this study investigated renal, cardiovascular, and safety outcomes of adding SGLT2is to insulin therapy in T2DM patients by researching databases like Embase, PubMed, and Cochrane libraries for reports published up to Feb 2023.

The researcher included RCTs comparing SGLT2is and insulin combination therapy (SGLT2is + INS group) with insulin therapy alone (INS group) in the relevant groups of patients.

The results of the study are:

• 14 RCTs were included.
• There were six thousand one hundred twenty subjects with 12-104 weeks durations included.
• The SGLT2is + INS group had reduced glycosylated haemoglobin values and insulin dosages compared to the insulin group.
• SGLT2is + INS group had a reduced urinary albumin/creatinine ratio (UACR) by 25.42 mg/g and uric acid concentration.
• There were no changes in the eGFR and renal-related adverse events.
• There were lower BP and body weight values in the SGLT2is + INS group.
• The genital infection risk was greater on adding SGLT2is to insulin therapy.
• Researchers found severe hypoglycemia or UTI risk to be equal between the two groups.

The team said that adding SGLT2is to insulin therapy is tied to better glucose control and decreased albuminuria, uric acid, BP and body weight without affecting eGFR in type 2 diabetes patients.

Further reading:

https://pubmed.ncbi.nlm.nih.gov/37515749/